source
- J&J's IBD combo therapy misses statistical goal but will be tested in a focused patient subgroupJohnson & Johnson reported that its experimental combination of Tremfya and Simponi, called JNJ-4804, did not achieve a statistically significant improvement in a Phase 2b study of inflammatory bow…
- Pfizer CEO Albert Bourla rules out any transformative merger plansOn the May 5, 2026 earnings call, Pfizer chief Albert Bourla was asked whether the company was considering a transformative merger in the near or medium term. Bourla answered that Pfizer has no pl…